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SUMMARY. The study was conducted to evaluate the bioequivalence of deferiprone 500 mg with innova-
tor drug in Pakistani men. Twenty four healthy volunteers were enrolled in this study. Each volunteer
take two tablets of generic and innovator deferiprone with two-week washout period. Blood samples were
collected at predetermined time intervals. Plasma deferiprone levels were analyzed using validated HPLC
method. Pharmacokinetic parameters computed non-compartmentally after logarithmic transformation
of data. The mean relative bioavailability was 104 %. The mean Cmax, AUC0–t, AUC0–∞ for generic drug
were 14.41, 40.49, and 42.84 μg.h/mL and for innovator were 12.68, 38.63, and 40.75 μg.h/mL, respective-
ly. Mean ratio (generic/innovator) of AUC0–t at 90 % CI was 0.9737-1.1150 and for Cmax was 0.99876-
1.2425. Hence, the mean ratio of 90 % confidence interval of AUC0–t and Cmax lie within the acceptable
limit of (0.80-1.25) for bioequivalence. Therefore, it was concluded that Ferinil and Ferriprox was proved
to be bioequivalent in healthy Pakistani men.
